Effect of isolevuglandin in HDL structure-function in atherosclerosis
异左旋黄素对动脉粥样硬化HDL结构功能的影响
基本信息
- 批准号:9767276
- 负责人:
- 金额:$ 6.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-06 至 2020-09-05
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAntiatherogenicApolipoprotein A-IApolipoprotein A-IIApolipoproteinsArterial Fatty StreakAtherosclerosisBiomedical EngineeringCardiovascular DiseasesCell DeathCellsCessation of lifeCholesterolChylomicronsClinicalDevelopmentDrug Delivery SystemsEndothelial CellsFamilial HypercholesterolemiaFamilyFellowshipFutureGoalsHigh Density Lipoprotein CholesterolHigh Density LipoproteinsHypertensionImpairmentIn VitroInflammationInflammatoryInflammatory ResponseInterleukin-1 betaLDL Cholesterol LipoproteinsLaboratoriesLinkLipid BiochemistryLipidsLipoproteinsLow-Density LipoproteinsLysineMass Spectrum AnalysisMediatingMentorsMetabolismModificationMusObesityOxidative StressPeroxidasesPharmacologyPhosphatidylcholine-Sterol O-AcyltransferasePhosphatidylethanolaminePhospholipidsPlasmaPlasma ProteinsPost-Translational Protein ProcessingPreventionPropertyProteinsResearchResearch PersonnelResearch Project GrantsRoleStructural ProteinStructureTestingTrainingTraining ProgramsUnited Statesadductanalogatherogenesisbasecardiovascular disorder riskcardiovascular risk factorcareercrosslinkdrinking waterefficacy testingexperiencehypercholesterolemiain vivolipophilicitymacrophagemortalitynovel therapeuticsoxidationoxidized lipidparticlepreservationpreventprogramsprotein structureresponsereverse cholesterol transportsmall moleculestructural biology
项目摘要
Project Summary
Cardiovascular diseases (CVD) account for one of every three deaths in the United States and are
ranked as the leading cause of mortality worldwide. While significant effort has been directed towards
elucidating the mechanisms governing the initiation and progression of CVD, much remains unclear. High
density lipoprotein (HDL) is regarded to be protective against CVD due to its many anti-atherogenic properties,
such as removing excess cholesterol from cells, preventing inflammation, and preventing cell death. Current
evidence suggests that the risk for CVD depends more on HDL particle functionality, rather than HDL-
cholesterol (HDL-C) levels.
Risk factors for CVD including obesity, hypercholesterolemia, and hypertension increase oxidative
stress and the formation of lipid dicarbonyls. Oxidative stress generates isolevuglandins (isoLGs), a family of
high reactive lipid dicarbonyls that react with lysine residues of proteins and headgroups of
phosphatidylethanolamines (PEs). Importantly, isoLG adduct levels are elevated in atherosclerosis, and
correlate with CVD risk more strongly than low-density lipoprotein (LDL) and cholesterol levels. Interestingly,
these isoLG adducts are not associated with LDL to a significant degree, raising the possibility that isoLG
preferentially modifies HDL and impairs its anti-atherogenic functions.
Given
the many important functions of
HDL, determining the consequences of isoLG modification on HDL structure, composition, and function is
imperative for developing novel therapeutics to protect against atherosclerosis.
My research plan will utilize a combination of structural biology, mass spectrometry, in vitro and in vivo
approaches, and small molecule scavengers to: i) determine the functional consequences of isoLG
modification on HDL subpopulations; ii) define the specific localization of isoLG adducts on HDL structural
proteins; iii) determine the specific component of HDL (protein versus lipid) that is responsible for inflammation;
iv) test the efficacy of isoLG scavengers in reducing atherosclerosis in vivo; v) compare analogues of
scavengers in their abilities to preserve HDL structure-function in vitro. The goal of all my aims is to develop an
understanding of the contribution of lipid dicarbonyl modification of HDL in atherogenesis. My long-term
research goals are to identify the contributions of oxidized lipids in altering lipoprotein function and metabolism
(LDL, HDL, chylomicrons), and to develop effective strategies to target specific mechanisms that contribute to
atherosclerosis initiation and progression. This fellowship will help me build a research program that will lead to
a productive career as an independent investigator of oxidative modifications of lipoproteins in CVD.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Linda Zhang其他文献
Linda Zhang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Antiatherogenic effects of neutrophil alpha defensins
中性粒细胞α防御素的抗动脉粥样硬化作用
- 批准号:
8360808 - 财政年份:2012
- 资助金额:
$ 6.56万 - 项目类别:
Antiatherogenic effects of neutrophil alpha defensins
中性粒细胞α防御素的抗动脉粥样硬化作用
- 批准号:
8505376 - 财政年份:2012
- 资助金额:
$ 6.56万 - 项目类别:
Antiatherogenic effects of high density lipoprotein and sphingosine 1-phosphate
高密度脂蛋白和1-磷酸鞘氨醇的抗动脉粥样硬化作用
- 批准号:
18590973 - 财政年份:2006
- 资助金额:
$ 6.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of the mechanisms for antiatherogenic effect of bone marrow AT2 receptor by using gene-targeted mice
基因靶向小鼠分析骨髓AT2受体抗动脉粥样硬化作用机制
- 批准号:
17590760 - 财政年份:2005
- 资助金额:
$ 6.56万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Antiatherogenic Properties of tert-Butylhydroquinone
叔丁基氢醌的抗动脉粥样硬化特性
- 批准号:
6786512 - 财政年份:2004
- 资助金额:
$ 6.56万 - 项目类别:
Antiatherogenic action of estrogen through inhibition of pathological proliferation in vascular smooth muscle sells
雌激素通过抑制血管平滑肌病理性增殖发挥抗动脉粥样硬化作用
- 批准号:
14370523 - 财政年份:2002
- 资助金额:
$ 6.56万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
ANTIATHEROGENIC EFFECTS OF MODERATE ALCOHOL USE
适量饮酒的抗动脉粥样硬化作用
- 批准号:
6115236 - 财政年份:1998
- 资助金额:
$ 6.56万 - 项目类别:
ANTIATHEROGENIC EFFECTS OF MODERATE ALCOHOL USE
适量饮酒的抗动脉粥样硬化作用
- 批准号:
6276470 - 财政年份:1997
- 资助金额:
$ 6.56万 - 项目类别:
ANTIATHEROGENIC EFFECTS OF MODERATE ALCOHOL USE
适量饮酒的抗动脉粥样硬化作用
- 批准号:
6168341 - 财政年份:1996
- 资助金额:
$ 6.56万 - 项目类别:
ANTIATHEROGENIC EFFECTS OF MODERATE ALCOHOL USE
适量饮酒的抗动脉粥样硬化作用
- 批准号:
2769196 - 财政年份:1996
- 资助金额:
$ 6.56万 - 项目类别:














{{item.name}}会员




